Bacterial resistance against antibiotics often involves multiple mechanisms that are 14 interconnected to ensure robust protection. So far, the knowledge about underlying 15 regulatory features of those resistance networks is sparse, since they can hardly be 16 determined by experimentation alone. Here, we present the first computational approach to 17 elucidate the interplay between multiple resistance modules against a single antibiotic, and 18 how regulatory network structure allows the cell to respond to and compensate for 19 perturbations of resistance. Based on the response of B. subtilis towards the cell wall 20 synthesis-inhibiting antibiotic bacitracin, we developed a mathematical model that 21 comprehensively describes the protective effect of two well-studied resistance modules 22 (BceAB and BcrC) on the progression of the lipid II cycle. By integrating experimental 23 measurements of expression levels, the model accurately predicts the efficacy of bacitracin 24 against the B. subtilis wild-type as well as mutant strains lacking one or both of the 25 resistance modules. Our study reveals that bacitracin-induced changes in the properties of 26 the lipid II cycle itself control the interplay between the two resistance modules. In particular,
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previous work (27) , such that for a given strain the relative luminescence units (RLU) 169 reported here are ~10-50 fold lower than previously reported. Also, in the present work we 170 used a more stringent cleaning procedure for test tubes (used for overnight-and 171 daycultures), which completely avoids the use of detergents and instead relies on 172 mechanical cleaning and autoclaving only. With this procedure we found that the basal 173 expression of cell wall stress modules (in the absence of antibiotics) is slightly lower than 174 with the previous procedure, explaining, for instance, why the observed luminescence activity 175 of the P bceA -lux construct in Figure 2B (iii) remains at a low level between 0 μg/ml and 3 x 10 -2 176 μg/ml bacitracin and only increases at higher antibiotic concentrations, while we found a 177 slight increase of luminescence activity at these concentrations before (27) . These subtle For concentration-dependent growth experiments, cells were grown as described for the 184 luciferase assays and OD 600 was measured analogously. The growth rate within the first hour 185 after bacitracin addition was determined to monitor the concentration-dependent effects of 186 bacitracin on cell growth ( Fig. 2B(i) ). The minimal inhibitory concentration (MIC) was defined 187 as the concentration of antibiotic that fully inhibited growth, i.e. for which the growth rate 
Results
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The common purpose of the UPP phosphatase BcrC and the ABC transporter BceAB is to 212 ensure progression of the lipid II cycle under bacitracin treatment, since bacitracin inhibits an 213 important step of this cycle ( Fig. 2A) . Consequently, to study the impact of the two resistance 214 modules on lipid II cycle homeostasis, we successively integrated the resistance modules 215 into a detailed computational description of the lipid II cycle (35). This previously established 216 theory predicts the rate of peptidoglycan synthesis (j PG ) of a B. subtilis strain devoid of any 217 inducible resistance determinants under antibiotic perturbation ( Fig. 2A, upper central panel) 218 and thus served as the basis of our mathematical model of the overall bacitracin resistance 219 network. In a first step, we included the BcrC module and studied its protective effect on the 220 lipid II cycle ( Fig. 2A, left panel) . In a second step, we investigated the interaction of the two 221 resistance modules by integrating the pre-existing theory of the BceAB module (21) into the 222 model ( Fig. 2A, right panel) . In this full model, we were able to study the impact of the two which the PG synthesis rate reaches its half-maximal level (IC 50 ) to higher values ( Fig. 2A with increasing levels of bacitracin, leading to a maximal ~6-fold induction at 3 μg/ml 241 bacitracin treatment compared to the untreated condition. In contrast, wild-type cells only 242 displayed a ~3-fold P bcrC induction reached at 10-fold higher bacitracin levels (30 μg/ml) (Fig. 
243
2B(i), black), suggesting that the additional expression of bceAB in the wild-type mitigates 244 the demand for bcrC expression, as discussed further below. Furthermore, we investigated 245 the impact of the BcrC resistance module on bacitracin resistance, by comparing the growth 246 of a ΔbceAB mutant and a ΔbceABΔbcrC double mutant. In doing so, we were able to study 247 the resistance contribution of BcrC alone, and avoided any compensatory upregulation of 248 bceAB expression that may complicate the interpretation of a comparison between wild-type 249 and a ΔbcrC mutant strain. By defining the MIC as the lowest antibiotic concentration leading 250 to zero growth rate after bacitracin addition, we observed a 2.3-fold lower MIC value for the 251 ΔbceABΔbcrC mutant ( Fig. 2B( 
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Hence, within the simulated range of BcrC and UppP contributions to the overall 311 phosphatase activity, the lack of BcrC was predicted to reduce the rate of PG synthesis 312 below its half-maximum for some of the parameters tested. Furthermore, the model predicted 313 relatively low IC 50 values since the overall PG synthesis rate was already reduced and very 314 small amounts of bacitracin should be sufficient to further decrease it to the assumed critical 315 rate of 50% of its optimal level.
316
However, such a reduction in the overall rate of PG synthesis even without bacitracin 317 treatment would cause clear defects in cell growth, which was neither observable in the 318 absence of bacitracin nor under low bacitracin concentrations when monitoring the growth of 319 ΔbceABΔbcrC mutant strain. Instead, the growth rate of the double mutant was only slightly 320 affected without bacitracin ( Supplementary Fig. S1 ) and the experimentally determined MIC 321 ( Fig. 2B (ii), light blue) was significantly higher than the IC 50 values predicted by the model.
322
These results led us speculate that B. subtilis uses additional routes to respond to the 323 deletion of bcrCthereby ensuring a close-to-optimal rate of PG synthesisprobably by 324 increasing the concentrations of lipid II. How does the cell implement this homeostatic 325 control? As previous studies revealed, σ M not only regulates the expression of bcrC in 326 response to bacitracin, but also induces individual steps of the methylerythritol phosphate 327 (MEP) pathway (e.g. ispD-F), which is responsible for early steps of lipid carrier (UPP) 328 synthesis (31, 38). Indeed, it was shown that the expression of σ M itself is significantly 329 increased in a mutant strain lacking BcrC (15). Hence, we hypothesized that the lipid II 330 concentrations might be homeostatically regulated by σ M -dependent control of the production 331 of new lipid carrier. To test this hypothesis, we used RT-qPCR to quantify transcript levels of 332 σ M -regulated genes involved in the production of UPP synthesis. As illustrated in Fig. 4B , we 333 found that during exponential growth in LB medium (without bacitracin) expression of both 334 ispD and ispF was 2-fold higher in the bcrC deletion strain compared to the wild-type strain.
335
Furthermore, the UPP synthetase encoded by uppS, which is not part of the σ M -regulon, did not show differential expression between both strains (Fig. 4B ). These results suggest that 337 the upregulation of early steps of UPP synthesis in a bcrC deletion mutant may increase the 338 overall abundance of lipid carriers in the lipid II cycle, thereby counteracting the bottleneck 339 induced by UPP phosphatase deletion.
340
Hence, we asked how a higher total concentration of the lipid II cycle intermediates 341 (in the following referred to as "LII intermediates") would affect the model prediction for a 342 bcrC deletion mutant (see Supplementary Text for a detailed description). As we did not 343 know the precise change in LII intermediates in the bcrC deletion strain, we simulated the 344 model for different fold-changes in LII intermediates and predicted the IC 50 under bacitracin 345 treatment. Here it turned out that an increase in LII intermediates raises both the lipid II 346 concentrations and the overall PG synthesis rate ( Fig. 5C ) and thus, ensures progression of 347 the lipid II cycle without bacitracin treatmentas suggested by the fact that growth of the 348 bcrC deletion strain was not drastically reduced when compared to the wildtype 349 ( Supplementary Fig. S1 ). Accordingly, the model predicts that higher levels of LII 
where is the UPP-BAC concentration at which the catalytic rate of BceAB reaches its 392 half-maximal value. Importantly, within this model not only sets the rate at which UPP is 393 released from the inhibitory grip of bacitracin, but also regulates expression of bceAB 394 expression via the flux-sensing mechanism depicted in Fig. 2A and 
399
We then asked whether this full model is in quantitative agreement with the data 400 describing the bacitracin response of the BceAB module in wild-type cells. To this end, we 401 fixed all parameters for the lipid II cycle to the optimal values derived above and imposed 402 that the regulation of BcrC protein levels is proportional to the P bcrC promoter activity 403 measured in the wild-type strain (Fig. 2B(i) ; black data). Then we estimated the additional 404 parameters describing the induction of the BceAB resistance module by a fit to the 405 experimental P bceA promoter activity ( Fig. 2B(iii) , black data); see Materials and Methods for 406 details of the fitting procedure and Supplementary Table 3 for parameter values. This led us 407 to a parameter combination for which the model output closely resembles the observed 408 response of P bceA towards bacitracin ( Fig. 6A ), suggesting that the model accurately captures 409 the cross-regulation between the two resistance modules. Importantly, when studying the PG 410 synthesis rate within this model ( Fig. 6B; black line) , it turned out that with increasing 411 bacitracin concentration the increasing production of BcrC and BceAB stabilized the PG 412 synthesis rate even in the presence of bacitracin, and increased the IC 50 to a value close to 413 the MIC experimentally measured in the wild-type strain ( Fig. 6B; black To further test the validity of our model, we demanded that it should be able to 419 correctly predict the behaviour of a ΔbcrC strain, in which BceAB is the sole genuine 420 resistance determinant under bacitracin treatment ( Fig. 6A; red data points) . Due to the lack 421 of BcrC in this strain, our model predicts that these cells produce higher levels of LII
422
intermediates (similar to the ΔbcrCΔbceAB double mutant), which also leads to a higher 423 abundance of UPP in the cell. This increased exposure of UPP then leads to higher levels of 424 the bacitracin-bound form UPP-BAC in the presence of the antibiotic, which in turn serves as 425 the stimulus for the activation of the P bceA promoter via the previously described flux-sensing 426 mechanism. Accordingly, our model predicts that the accumulation of UPP-BAC in the ΔbcrC 427 strain triggers a ~10-fold higher P bceA promoter activity compared to the wild-type strain (Fig.
428
6A; red dashed line), in qualitative agreement with the increased P bceA activity in the ΔbcrC 429 strain determined experimentally ( Fig. 6A; red data points) . Also, without invoking any further 
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One striking discrepancy between our model and the experimental data, however,
436
was visible in the absence of bacitracin, where our experiments showed that the promoter 437 activity of P bceA was also ~10-fold higher than in the wild-type (Fig. 6A ). This result is not 438 compatible with the idea that UPP-BAC is the sole substrate for the flux-sensing mechanism 439 via the BceAB transporter (triggering the activation of P bceA ), because UPP-BAC cannot be 440 formed in the absence of bacitracin and thus the signalling mechanism should be inactive.
441
However, it was previously hypothesized that UPP itself somehow triggers (futile?) ATP into a pre-existing theory of the lipid II cycle, we showed that the interplay between the two 484 major resistance determinants (BceAB and BcrC) is strictly linked to the properties of the lipid 485 II cycle, which change in response to bacitracin.
486
One important insight of our analysis is that BcrC is the more dominant UPP 487 phosphatase compared to UppP -dictating the bulk of the overall UPP recycling rate in the 488 lipid II cycle of B. subtilis. This is also reflected by the fact that bcrC expression is 489 significantly elevated under bacitracin stress ( Fig. 2B(i) ), while uppP is constitutively 490 expressed (14-16), implying even more pronounced changes in the total phosphatase activity 491 in response to bacitracin than previously appreciated. 
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To counteract the depletion of the lipid II pool caused by a shortage of UPP phosphatase activity, we found two σ M -controlled genes, ispD and ispF, involved in the de novo synthesis 502 of UPP to be significantly up-regulated. While we did not directly prove that this leads to an 503 increase in the overall abundance of lipid II cycle intermediates, our experimental and 504 theoretical results indirectly support this hypothesis in three ways: (1) The ΔbcrCΔbceAB 505 double mutant is significantly more resistant to bacitracin than naively predicted by a model 506 with constant total lipid II cycle intermediate pools, suggesting that a compensatory up-507 regulation of these pools contributes to bacitracin resistance in this mutant.
(2) Under 508 bacitracin treatment the P bceA promoter is ~10-fold more active in a ΔbcrC mutant compared 509 to the wild-type, suggesting that the major substrate, UPP-BAC, of the BceAB transporter is 510 more abundant in the mutant, which in turn triggers stronger activation of P bceA via the flux-511 sensing mechanism described in (21).
(3) Even in the absence of bacitracin the ΔbcrC 512 mutant displays a ~10-fold higher P bceA activity than the wild-type, suggesting that the 513 elevated UPP pool in this mutant is sufficient to trigger some futile ATP hydrolysis by the 514 BceAB transporter, which then activates P bceA via the flux-sensing mechanism. 
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We suggest that this strategy implements a robust way of ensuring lipid II cycle homeostasis. 
548
We showed that a simple existing model can be expanded to develop a more and more 549 complex picture, and eventually the model itself could even become a building block when 550 describing a network on a broader scale. This approach can act as a blueprint for acquiring 551 true systems-level understanding of complex regulatory structures, not only describing the 552 organisation of resistance system against other antibiotics, but also more generally multi-553 tiered response networks that can be expected across many bacterial species and a range of 560 Table S1 561 Table S2 562 growth rates, which are obtained as the average growth rates of strains carrying the different 728 reporter constructs, but sharing the same genotype. Measurements were performed during 729 exponential growth phase in LB medium at 37ºC in a microtiter plate reader. Data are shown 730 for strains TMB1619 (wild-type strain W168 sacA::pCHlux103 (P bceA -lux), TMB1620 (wild-731 type strain W168 sacA::pCHlux104 (P bcrC -lux)), TMB1623 (W168 bceAB::kan sacA::pCHlux103 (P bceA -lux)), TMB1624 (W168 bceAB::kan sacA::pCHlux104 (P bcrC -lux)), 733 TMB1627 (W168 bcrC::tet sacA::pCHlux103 (P bceA -lux)), TMB1628 (W168 bcrC::tet 734 sacA::pCHlux104 (P bcrC -lux)) and TMB1632 (W168 bceAB::kan bcrC::tet sacA::pCHlux104 735 (P bcrC -lux)), see Table S1 . Data points and error bars indicate means and standard deviations 736 derived from at least three biological replicates. Note that we did not test P bceA -luxABCDE 737 activity in strains carrying a ΔbceAB deletion, because the flux-sensing mechanism activating 738 P bceA strictly relies the presence of BceAB (21) Fig. 2A) Fig. 3C, D) . The 
